Apatinib 250 mg/day, continuous administration

2 trials

Sponsors

The Affiliated Tumor Hospital of Guangxi Medical University

Conditions

lung cancer

Phase 4

The prospective, non-interventional clinical study of carelizumab combined with apatinib in the second-line treatment of advanced non-small cell lung cancer

Active, not recruitingChiCTR2000034455

The Affiliated Tumor Hospital of Guangxi Medical Universitylung cancer

Start: 2020-07-03Updated: 2020-07-06

The prospective, non-interventional clinical study for carelizumab combined with apatinib in the first-line treatment of advanced non-small cell lung cancer

RecruitingChiCTR2000034486

The Affiliated Tumor Hospital of Guangxi Medical Universitylung cancer

Start: 2020-07-03Updated: 2020-07-13